Since 1989, the United States government has operated the National Vaccine Injury Compensation Program (VICP). This federal initiative was designed to provide a streamlined legal pathway for individuals who suffer rare adverse reactions to vaccines, having distributed over $5.5 billion in claims since its inception. The program serves as a 'no-fault' system, intended to protect both vaccine manufacturers from excessive litigation and patients from the complexities of proving liability in court.

Recently, the program has become a focal point of political discourse. Robert F. Kennedy Jr., a prominent critic of current public health policies, has publicly advocated for the dismantling or significant restructuring of the program. Supporters of the VICP argue that it is a vital shield for public health, ensuring that the vaccine supply chain remains stable and that injured parties receive necessary financial support. Conversely, opponents of the current structure suggest that the program may shield pharmaceutical companies from accountability and that the criteria for compensation should be re-evaluated.

While the program's history is well-documented, the debate centers on whether the current model remains the most effective way to balance public health needs with individual rights. There is disagreement regarding the impact of potential changes; some analysts warn that removing the program could lead to a surge in lawsuits that might destabilize vaccine availability, while others argue that the current system lacks sufficient transparency and oversight.